Cell & Gene Therapy INSIGHTS

Innovation Insights August 2021

August 2021

  • Evolving technology trends and regulatory pathways in the tissue engineered product space

    W Fodor
    William Fodor
    Chief Scientific Officer, Biostage
    William Fodor received his B.S. degree in Genetics and his Ph.D. degree in Molecular Genetics from The Ohio State University. He then completed his post-doctoral training in Immunobiology at the Yale School of Medicine (Mentor, R.A. Flavell). Dr. Fodor started his industrial career as a founding scientist of Alexion Pharmaceuticals, Inc. During his tenure at Alexion he directed the xenotransplantation, cell and tissue and organ engineering programs and advanced the program to include a pilot manufacturing facility for cell production. Dr. Fodor then moved to academia as an Associate Professor in the Center for Regenerative Biology at the University of Connecticut where he spent 3 years renovating his research to focus on stem cell biology for tissue repair. Dr. Fodor then returned to industry as Senior Director of Product Development at Viacell Inc., where he was responsible for various stem cell product development projects for hematologic indications as well as islet stem cell applications for diabetes. Following his tenure at Viacell, he continued his career in biotechnology as an independent consultant, serving many clients within the regenerative medicine field. Dr. Fodor’s relationship with Biostage was first as a consultant then as the Chief Scientific Officer, his current role.
    17 August 2021
    Interview
  • Broadening horizons for extracellular vesicles as both therapeutic modality and delivery tool

    J Correia
    Joana Correia
    CEO, Exogenus Therapeutics
    Joana Correia co-founded Exogenus Therapeutics in 2015, after a successful participation in COHiTEC program for technology commercialization. Having been awarded several honors, including three entrepreneurship prizes (Everis Foundation Award, Young Entrepreneur ANJE, and Prémio Empreendedor XXI BPI/CaixaBank), Joana has raised €3.5M in funds for R&D, and is currently a leader in the field of EV–based therapeutics recognized internationally. With a PhD in Human Biology, she dedicated 20 years of her career to R&D in the area of human diseases and healthcare, is inventor of two patents, has several publications in high impact journals, and is invited researcher of the Center for Neuroscience and Cell Biology (CNC, Coimbra, Portugal). Joana is an enthusiastic entrepreneur and activist, with a creative mindset and a strong drive to solve healthcare challenges.
    17 August 2021
    Interview

Other reports from Cell and Gene Therapy insights